C-Bond Systems Signs Term Sheet to Acquire Gummy USA, SureDose, and Creative Manufacturing, Bringing Precision Dosing to the $25 Billion Gummy Industry
C-Bond Systems (OTC PINK:CBNT) has signed a term sheet to acquire Gummy USA, SureDose, and Creative Manufacturing, companies operating in the $25 billion nutraceutical gummy industry. The acquisition targets possess patent-pending technology for precise dosing in nutraceutical and pharmaceutical gummies through their proprietary SureDose process.
The SureDose technology achieves dosing accuracy within 3% (sometimes under 1%), significantly outperforming current FDA standards that require 10% variance for nutraceuticals and 5% for pharmaceuticals. Don Swanson, owner of the acquired companies, will become Chairman and CTO of the combined entity, while Scott R. Silverman will continue as CEO.
Gummy USA currently serves several significant customers with active purchase orders, with additional agreements in development. The non-binding term sheet is expected to close within 60 days due to anticipated growth and demand.
C-Bond Systems (OTC PINK:CBNT) ha firmato un accordo preliminare per acquisire Gummy USA, SureDose e Creative Manufacturing, aziende che operano nel settore dei gummy nutraceutici del valore di 25 miliardi di dollari. Le aziende target dell'acquisizione possiedono una tecnologia in attesa di brevetto per il dosaggio preciso nei gummy nutraceutici e farmaceutici grazie al loro processo proprietario SureDose.
La tecnologia SureDose raggiunge un'accuratezza di dosaggio del 3% (a volte sotto l'1%), superando significativamente gli attuali standard della FDA che richiedono una variazione del 10% per i nutraceutici e del 5% per i farmaceutici. Don Swanson, proprietario delle aziende acquisite, diventerà Presidente e CTO dell'entità combinata, mentre Scott R. Silverman continuerà a ricoprire il ruolo di CEO.
Gummy USA attualmente serve diversi clienti significativi con ordini di acquisto attivi, con ulteriori accordi in fase di sviluppo. Si prevede che l'accordo preliminare si chiuda entro 60 giorni a causa della crescita e della domanda previste.
C-Bond Systems (OTC PINK:CBNT) ha firmado un acuerdo preliminar para adquirir Gummy USA, SureDose y Creative Manufacturing, empresas que operan en la industria de gomitas nutracéuticas de 25 mil millones de dólares. Las empresas objeto de la adquisición poseen una tecnología pendiente de patente para dosificación precisa en gomitas nutracéuticas y farmacéuticas a través de su proceso propietario SureDose.
La tecnología SureDose logra una precisión de dosificación dentro del 3% (a veces menos del 1%), superando significativamente los estándares actuales de la FDA que requieren una variación del 10% para nutracéuticos y del 5% para farmacéuticos. Don Swanson, propietario de las empresas adquiridas, se convertirá en Presidente y CTO de la entidad combinada, mientras que Scott R. Silverman continuará como CEO.
Gummy USA actualmente atiende a varios clientes importantes con pedidos de compra activos, y se están desarrollando acuerdos adicionales. Se espera que el acuerdo preliminar se cierre dentro de 60 días debido al crecimiento y la demanda anticipados.
C-Bond Systems (OTC PINK:CBNT)는 250억 달러 규모의 영양소 젤리 산업에서 운영되는 Gummy USA, SureDose 및 Creative Manufacturing을 인수하기 위한 계약을 체결했습니다. 인수 대상 기업들은 그들의 독점적인 SureDose 프로세스를 통해 영양소 및 제약 젤리에서 정확한 복용량을 위한 특허 출원 기술을 보유하고 있습니다.
SureDose 기술은 3% 이내(때로는 1% 미만)의 복용량 정확도를 달성하여, 영양소에 대해 10% 변동을 요구하는 FDA의 현재 기준과 제약에 대해 5%를 요구하는 기준을 현저히 초과합니다. 인수된 회사의 소유자인 Don Swanson은 결합된 법인의 회장 겸 CTO가 되며, Scott R. Silverman은 CEO로 계속 활동합니다.
Gummy USA는 현재 여러 주요 고객에게 활성 구매 주문을 제공하고 있으며, 추가 협약도 개발 중입니다. 예상되는 성장과 수요로 인해 비구속성 계약서는 60일 이내에 마감될 것으로 예상됩니다.
C-Bond Systems (OTC PINK:CBNT) a signé une feuille de terme pour acquérir Gummy USA, SureDose et Creative Manufacturing, des entreprises opérant dans l' industrie des gommes nutraceutiques de 25 milliards de dollars. Les cibles d'acquisition possèdent une technologie en attente de brevet pour un dosage précis dans les gommes nutraceutiques et pharmaceutiques via leur processus propriétaire SureDose.
La technologie SureDose atteint une précision de dosage de 3% (parfois sous 1%), surpassant significativement les normes actuelles de la FDA qui exigent une variation de 10% pour les nutraceutiques et de 5% pour les pharmaceutiques. Don Swanson, propriétaire des entreprises acquises, deviendra Président et CTO de l'entité combinée, tandis que Scott R. Silverman continuera en tant que CEO.
Gummy USA dessert actuellement plusieurs clients importants avec des commandes en cours, et des accords supplémentaires sont en cours de développement. On s'attend à ce que la feuille de terme non contraignante se clôture dans les 60 jours en raison de la croissance et de la demande anticipées.
C-Bond Systems (OTC PINK:CBNT) hat ein Absichtserklärung zur Übernahme von Gummy USA, SureDose und Creative Manufacturing unterzeichnet, Unternehmen, die in der 25-Milliarden-Dollar-Nutraceutical-Gummibärchenindustrie tätig sind. Die Akquisitionsziele verfügen über patentierte Technologie zur genauen Dosierung in nutraceutical und pharmazeutischen Gummis durch ihren proprietären SureDose-Prozess.
Die SureDose-Technologie erreicht eine Dosierungsgenauigkeit von 3% (manchmal unter 1%), was die aktuellen FDA-Standards, die eine Abweichung von 10% für Nutraceuticals und 5% für Pharmazeutika erfordern, erheblich übertrifft. Don Swanson, Eigentümer der übernommenen Unternehmen, wird Vorstandsvorsitzender und CTO der fusionierten Einheit, während Scott R. Silverman weiterhin als CEO tätig bleibt.
Gummy USA bedient derzeit mehrere bedeutende Kunden mit aktiven Bestellungen und weitere Vereinbarungen sind in Entwicklung. Es wird erwartet, dass die nicht verbindliche Absichtserklärung innerhalb von 60 Tagen aufgrund des erwarteten Wachstums und der Nachfrage abgeschlossen wird.
- Revolutionary technology achieving 3% dosing accuracy vs FDA standards of 10% for nutraceuticals
- Existing customer base with active purchase orders
- Entry into $25 billion nutraceutical gummy market
- Experienced leadership addition with Don Swanson as Chairman/CTO
- Non-binding term sheet with no guaranteed closing
- 60-day closing timeline may face delays
- Financial terms of acquisition not disclosed
The companies have patent-pending technology for more precise dosing for nutraceuticals and pharmaceuticals using its SureDose™ process
Don Swanson, principal of Gummy USA, SureDose, and Creative Manufacturing will become Chairman of the combined entity
POMPANO BEACH, FL / ACCESS Newswire / February 11, 2025 / C-Bond Systems (the "Company" or "C-Bond") (OTC PINK:CBNT) today announced that it has entered into a term sheet to acquire the assets of Gummy USA, LLC, SureDose, LLC, and Creative Manufacturing, LLC, players in the
Gummy USA, SureDose, and Creative Manufacturing are owned and operated by Don Swanson, a recognized innovator in nutraceutical, OTC, and pharmaceutical gummy manufacturing and dosing technology. Following the closing of the acquisition, Swanson will serve as Chairman, Chief Technology Officer (CTO), and majority shareholder of the newly combined entity. Scott R. Silverman will continue as CEO, and the Company's Board of Directors is expected to include Swanson, Silverman, and Jay Hill, a career technology executive with extensive sales, marketing, corporate development, and board experience.
Advancing Precision Dosing in the Gummy Industry
Swanson brings over eight years of pharmaceutical manufacturing experience, having designed and developed state-of-the-art gummy production facilities both domestically and internationally. His deep understanding of gummy manufacturing equipment led him to identify and address a critical gap in dosing precision and production efficiency. Under his leadership, SureDose has pioneered advancements to significantly improve accuracy, quality, and compliance with gummy industry standards.
The need for greater dosing accuracy in the gummy industry is widely recognized. Current FDA standards require nutraceutical dosing within
A Growing Market with Strong Demand
Gummy USA currently serves several significant customers and has active purchase orders, with additional agreements in development as its precision dosing units become available for licensing in select facilities.
"We believe our best-in-class technology can revolutionize the gummy industry by enhancing dosing accuracy and setting new standards for nutraceutical, OTC, and pharmaceutical manufacturers," said Swanson, Chairman and CTO. "We believe that by adopting the SureDose delivery system, companies can ensure superior quality and consistency, ultimately improving the consumer and patient experience."
Next Steps in the Acquisition Process
The term sheet is non-binding, and both parties will use their best efforts to complete the transaction within the next 60 days due to anticipated growth and demand.
About C-Bond
C-Bond Systems, Inc. (OTC: CBNT) markets the patented C-Bond technology, which is independently proven to strengthen glass in architectural applications. For more information, please visit our website: www.cbondsystems.com.
Forward-Looking Statements
Statements in this press release about our future expectations, including the likelihood that following the closing of the acquisition, Swanson will serve as Chairman, Chief Technology Officer (CTO), and majority shareholder of the newly combined entity; the likelihood that Silverman will continue as CEO, and the Company's Board of Directors is expected to include Swanson, Silverman, and Jay Hill; the likelihood that SureDose could establish a new gold standard in nutraceutical and pharmaceutical gummy production, ensuring higher precision, improved efficacy, and better regulatory alignment; the likelihood that our best-in-class technology can revolutionize the gummy industry by enhancing dosing accuracy and setting new standards for nutraceutical, OTC, and pharmaceutical manufacturers; the likelihood that by adopting the SureDose delivery system, companies can ensure superior quality and consistency, ultimately improving the consumer and patient experience; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to successfully commercialize its products; the likelihood of the transaction closing; the Company's ability to raise capital; regulatory risks; as well as other risks. Additional information about these and other factors may be described in the Company's filings with the Securities and Exchange Commission ("SEC") including its Form 10-K filed on April 1, 2024, its Forms 10-Q filed on November 14, 2024, August 19, 2024, and May 14, 2024, and in future filings with the SEC. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Allison Tomek
C-Bond Systems
atomek@cbondsystems.com
SOURCE: C-Bond Systems, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the dosing accuracy of CBNT's SureDose technology compared to FDA standards?
When is the expected closing date for CBNT's acquisition of Gummy USA?
What is the market size for the gummy industry that CBNT is entering?
Who will lead the combined company after CBNT's acquisition of Gummy USA?
What companies is CBNT acquiring in the gummy industry?
